Hikal Ltd

- There is no explicit mention of any ongoing or planned new fundraising through debt or equity in the provided transcript. - The discussion about funding challenges mainly pertains to the pharma space, especially funding for Phase I/II molecules and smaller biotech customers facing slowdowns. - Hikal management stated they are not deeply involved in Phase II, III funding challenges and did not indicate any need to raise funds currently. - Capex plans are primarily funded through internal resources, with INR200 crores planned for the current year and INR500 crores CWIP ongoing. - No indications or announcements related to new equity or debt fundraising were discussed during the Q&A or management commentary.

- Hikal Limited is undertaking significant capital expenditure (capex), targeting INR 200 crores in the current financial year, with about INR 170 crores already incurred and the balance expected soon. - A major ongoing project is the commissioning of a new multipurpose plant at Panoli, part of an INR 500 crores investment MoU signed with the Gujarat government. - This new plant is anticipated to be operational by Q1 or Q2 of the coming quarters and will primarily cater to crop protection with a focus on backward integration. - Future capex beyond the current year is expected to be moderate, with INR 30-40 crores planned in the next quarter. - The company aims to fully capitalize and operationalize the INR 500 crores CWIP with total capex over two years expected to be around INR 700 crores. - These investments are strategic, aimed at growing the CDMO business and enhancing long-term capacities across pharma, animal health, and crop protection segments.

- Revenue and margins expected to pick up from the second half of FY '25, reaching pre-COVID levels. - Pharma business volumes and margins are recovering, with a full revival anticipated by H2 FY '25. - Crop Protection currently faces destocking, expected to normalize and improve from Q3 or Q4 of the next financial year (FY '25). - Medium to long-term industry fundamentals remain intact despite short-term challenges. - Double-digit revenue growth expected post-normalization, targeting INR 3,000+ crores by FY '27–'28 from INR 2,000+ crores currently. - Focus on growing CDMO business significantly, with a rising share in overall revenue expected over the next 3-4 years. - Animal Health segment projected to contribute INR 200-300 crore revenue within 3-4 years, with ramp-up beginning FY '25. - Continuous new product launches in Pharma (3-4 products annually) supporting growth. - Capex of INR 200 crore planned for FY '24, aiding capacity expansion and future growth.

- Hikal expects revenue and margins to normalize and improve to pre-COVID levels by the second half of FY '25. - Growth driven by revival in Pharma (API and CDMO) and Crop Protection segments, with volumes and margins recovering. - CDMO business share is targeted to increase significantly over the next 3-4 years, supporting margin expansion. - EBITDA margins are expected to improve from current levels (~14-15%) back to earlier steady-state levels around 18-19%, possibly higher. - Operating leverage from recent capex (~INR500-700 crores) and new multipurpose facilities commissioning will support margin expansion. - Medium to long-term outlook is positive with potential double-digit revenue growth and margin expansion up to 23-25% EBITDA over next 3-4 years. - Animal Health business and new projects expected to contribute to future growth and profitability. - Overall, Hikal aims for significant earnings growth and margin improvement by FY '27-'28 aligned with industry normalization and capex ramp-up.

- The transcript does not explicitly mention the current or expected order book or pending orders in specific figures. - However, it notes a "robust pipeline" of projects in the CDMO space, indicating healthy ongoing and potential future orders. - There are "several projects under advanced stage of discussion with existing innovator customers as well as new customers" in the Crop Protection business, signaling strong order inflow prospects. - Post-incident reassurances leading to onboarding of new customers suggest an increase in the order book. - In Animal Health, discussions are underway with several customers at various stages, showing potential future orders. - Overall, continuous discussions with existing and potential clients imply a steady and growing order book aligned with the company’s growth plans.